(文/解红娟 编辑/张广凯) "该辟谣的都辟谣了。" 在业内人士看来，尽管目前尚未有官方明确通知，但瑞士联邦食品安全局（BLV）的相关结论，已然变 相坐实了此次涉事ARA（花生四烯酸）原料的供应商正是嘉必优。 近日，瑞士《每日广讯报》（Tages-Anzeiger）报道，瑞士联邦食品安全局（BLV）表示，受污染的微 量原料花生四烯酸（ARA）来自中国供应商，该公司是全球三大ARA生产商之一。 此消息一出，作为国内ARA行业龙头企业的嘉必优，瞬间被推至舆论风口浪尖。 观察者网了解到，全球ARA市场的三大核心生产商分别为荷兰帝斯曼-芬美意、中国嘉必优以及中国润 科生物。在污染事件爆发后，帝斯曼-芬美意、中国润科生物均迅速发声撇清关联，唯有嘉必优始终没 有正面回应。 具体来看，帝斯曼-芬美意明确表示"涉事问题ARA原料并非由其供应"，并称作为全球ARA营养原料的 长期可靠供应商，始终将产品质量与安全置于首位，其生产的life's ARA完全按照全球最高婴配级标准 生产，确保每一步都可控、可溯、可靠。 同时，帝斯曼-芬美意还透露，受此次事件影响，其ARA原料需求激增，公司将全力协调产能以满足市 场需求。 润科生物则发 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网消费综合报道】继雀巢之后，法国乳制品企业拉克塔利斯也启动了大规模奶粉召回，这两起相 继发生的国际食品安全事件迅速波及国内产业链，将国内最大的ARA（花生四烯酸）供应商嘉必优 （688089.SH）推向了风口浪尖。 据央视新闻报道，1月21日，法国乳企拉克塔利斯公司宣布，在18个国家和地区召回多个批次的婴幼儿 奶粉，原因是相关产品可能含有蜡样芽孢杆菌毒素，存在引发腹泻和呕吐等风险。此前在1月初，雀巢 也因供应商提供的一款ARA油脂原料存在质量问题，在欧洲多国对一批婴儿配方奶粉实施了预防性召 回。英国食品标准局指出，蜡样芽孢杆菌具有高度热稳定性，可能在冲调过程中存活，引发食源性疾 病。 针对雀巢的召回事件，国务院食安办、市场监管总局高度重视，已督促雀巢（中国）有限公司落实主体 责任，召回在中国境内销售的相关批次产品。在这一背景下，作为雀巢等国内外知名婴幼儿配方奶粉企 业的ARA供应商，嘉必优受到市场广泛关注。1月13日，嘉必优收到上交所监管工作函，督促其依法履 行信息披露义务，市场普遍认为这与雀巢奶粉召回事件高度相关。 图片来源 于海关总署进 ...

Core Viewpoint - The article discusses the recent crisis faced by Jia Bi You, a leading ARA (Arachidonic Acid) company in China, due to its involvement in a global recall initiated by Nestlé over potential contamination issues, which has led to regulatory scrutiny and market concerns [1][5]. Group 1: Regulatory Response - On January 12, the Shanghai Stock Exchange issued a regulatory letter to Jia Bi You, urging the company to respond promptly and fulfill its information disclosure obligations, although the specific content of the letter was not disclosed [3][11]. - Investors have linked the regulatory letter to the Nestlé recall incident, with expectations that Jia Bi You will need to clarify its role as a supplier and provide details on affected batches and risk management measures [11]. Group 2: Market Reaction - Following the recall announcement by Nestlé on January 5, which involved potential contamination of ARA raw materials, Jia Bi You's stock price fell by 11.91% on January 8 due to market anxiety over the company's silence amid the crisis [9][11]. - In contrast to other companies in the industry that quickly assured the safety of their products, Jia Bi You's delayed response has heightened market concerns [7][8]. Group 3: Financial Performance - Jia Bi You reported a total revenue of 428 million yuan for the third quarter, a year-on-year increase of 10.56%, and a net profit of 129 million yuan, reflecting a 54.18% increase [16]. - The company has shown improvements in profitability, with gross and net profit margins rising to 48.69% and 29.64%, respectively, driven by increased sales of ARA and DHA products [16]. Group 4: Insider Trading and Market Confidence - There has been a notable trend of insider selling, with key personnel, including core technical staff, selling shares shortly after the recall announcement, which has raised suspicions about their confidence in the company's future [18][19]. - Past instances of significant share reductions by major shareholders have contributed to a decline in market confidence regarding Jia Bi You's long-term prospects [19].

Core Viewpoint - Nestlé has initiated a recall of infant formula products in over 50 countries due to potential risks associated with the core nutritional additive ARA (Arachidonic Acid), raising concerns about raw material safety and supply chain management in the infant formula sector [1] Group 1: Company Responses - Feihe stated that all products containing ARA are safe for consumption and that their ARA is in powdered form, unlike the liquid ARA used in the recalled products [3] - Mengniu confirmed that their ARA suppliers are unrelated to the European recall incident and that all products undergo multiple quality checks before market release [3] - Danone emphasized that all their infant formula products are produced under high standards and do not use ARA from the implicated supplier [4] - Arla conducted a comprehensive review of their infant nutrition products and confirmed that their ARA is not affected by the issues related to the recall [4] Group 2: Regulatory Oversight - The State Council's Food Safety Office and the Market Supervision Administration have urged Nestlé (China) to effectively manage the recall of affected products, ensuring consumer rights are protected [2] - The recall in China involves four brands: Litojing, Platinum Enfamil, Shuyi Enfamil, and Wyeth S-26, totaling 30 batches of products [2] Group 3: Industry Implications - The incident highlights the urgent need for improved transparency in the food supply chain and the establishment of robust raw material traceability mechanisms [4] - There is a collective call for companies to strengthen their quality control systems and fulfill their responsibilities to maintain consumer confidence and ensure the healthy development of the industry [4]

Core Viewpoint - Nestlé has initiated a global recall of infant formula products due to potential quality issues with ARA (Arachidonic Acid) sourced from suppliers, affecting over 50 countries and raising public concern about the safety of infant formula ingredients [1] Group 1: Company Responses - Mengniu stated that its ARA raw material suppliers are unrelated to the European recall incident, and all products undergo strict quality control [3] - Feihe confirmed that its ARA raw materials are not affected by any issues related to Bacillus cereus toxins, and the company adheres to stringent quality standards [3] - Junlebao mentioned that its ARA suppliers are Roget and Runke Bio, and the company follows internal control standards that exceed national regulations [3] - Danone emphasized that all its infant formula products are produced under high standards and do not use ARA from the suppliers involved in the recall [4] - Arla conducted a comprehensive review of its infant nutrition products and confirmed that its ARA suppliers are not linked to the recall issues [4] - HiPP stated that the ARA used in its products is sourced from suppliers not involved in the recall, ensuring safety and reliability [4] Group 2: Regulatory Oversight - The State Council's Food Safety Office and the Market Supervision Administration have urged Nestlé (China) to effectively manage the recall of affected products in China, ensuring consumer rights are protected [2] - The recall in the Chinese market includes four brands: Litojing, Platinum Enfamil, Shuyi Enfamil, and Wyeth's children's growth milk powder, totaling 30 batches [2]

Core Viewpoint - Nestlé has initiated a precautionary recall of infant formula in 45 countries due to quality issues with raw materials from a supplier, although no adverse health reports have been received so far [1][4]. Group 1: Company Actions - Nestlé announced the recall of affected infant formula products in China, the UK, Germany, and other countries, emphasizing that its registered special medical infant formula products in China are not affected [1][4]. - The supplier of the problematic Arachidonic Acid (ARA) raw material has not been officially identified, but speculation points to a biotechnology company in Wuhan, Jia Bi You [1][4]. - Jia Bi You's stock fell over 13% following the news, closing down 11.91% at 21.15 yuan on January 8 [3]. Group 2: Industry Impact - ARA is a crucial component for infant brain and nervous system development, making it a key ingredient in infant formula [4]. - The quality issue involves a toxin from Bacillus cereus, which can cause gastrointestinal problems, although such occurrences are rare [4]. - Several dairy companies, including Danone and FrieslandCampina, have publicly stated that they do not use ARA from the implicated supplier, reinforcing their product safety [9][10]. Group 3: Supplier Dynamics - Jia Bi You is the largest ARA supplier in China and a significant player internationally, with established relationships with major infant formula brands [5][11]. - The company’s ARA business generated 390 million yuan, accounting for 70.27% of its total revenue, highlighting its reliance on this segment [11]. - The incident may negatively impact Jia Bi You's competitiveness and future market expansion, as other companies may have alternative ARA suppliers [11].

Core Viewpoint - The Nestlé infant formula recall has led to significant market disruptions, affecting not only Nestlé but also other brands and suppliers in the industry, with potential long-term impacts on consumer trust and brand reputation [2][3][4]. Group 1: Recall Details - On January 6, Nestlé announced a recall of certain batches of infant formula across 31 countries due to quality issues with ARA oil, which may contain Bacillus cereus, a bacteria that can cause foodborne illness [3][4]. - The recall involves 71 batches of products from Nestlé and Wyeth, covering at least 15 series of infant formula and one series of children's growth formula [3][4]. - Nestlé stated that the affected batches represent less than 0.5% of its annual sales, indicating a limited financial impact on the company [4]. Group 2: Market Reactions - Following the recall announcement, there has been a surge in irrational returns from customers, with some retailers reporting significant increases in return requests, regardless of whether the products were part of the affected batches [2][5]. - Competitors have begun to capitalize on the situation, with some brands actively promoting their products as safe alternatives [5]. - The recall has raised concerns about consumer sensitivity to quality issues in infant formula, which could lead to a more significant impact on Nestlé's market share in China compared to other regions [5]. Group 3: Impact on Suppliers - The recall has also affected multiple suppliers, with companies like Danone and HiPP clarifying that they do not use the implicated ARA supplier [7][8]. - DSM-Firmenich, the largest ARA supplier, confirmed that the problematic ARA was not produced by them, leading to increased demand for their ARA products [9][12]. - The A-share listed company, Jia Bi You, has been identified as a potential supplier of the problematic ARA, with its stock price dropping over 10% following the news [2][12][13]. Group 4: Financial Implications - In 2024, despite gaining market share, Nestlé's infant nutrition business in Greater China is projected to show negative growth, with an organic growth rate of -6.1% reported for the first three quarters of 2025 [6]. - Market data indicates that Nestlé and Wyeth hold a combined market share of approximately 9.3% in China's infant formula market, trailing behind competitors like Feihe and Danone [6].

Core Viewpoint - The Nestlé infant formula recall has led to significant market disruptions, affecting not only Nestlé but also other brands and suppliers in the industry, with potential long-term impacts on consumer trust and sales performance [1][2][3]. Group 1: Recall Details - On January 6, Nestlé announced a recall of certain batches of infant formula across 31 countries due to quality issues with ARA (arachidonic acid) oil, which may contain harmful bacteria [2][3]. - The recall involves 71 batches of products from Nestlé and Wyeth, affecting at least 15 series of infant formula and one series of children's growth formula [3][4]. - Nestlé's assessment indicates that the affected batches represent less than 0.5% of the group's annual sales, suggesting limited financial impact on the company [4]. Group 2: Market Reactions - Following the recall announcement, there has been a surge in irrational returns from customers, with some retailers reporting significant increases in return requests, regardless of whether the products were part of the affected batches [1][5]. - The recall has led to a decline in confidence among distributors, particularly affecting Nestlé's high-end infant formula "Platinum Enfamil," which may face severe market challenges [1][5]. Group 3: Impact on Competitors and Suppliers - Other infant formula brands and suppliers, including Danone and HiPP, have clarified that they do not use the implicated ARA supplier, distancing themselves from the recall [8][9]. - The largest ARA supplier, DSM-Firmenich, confirmed that the problematic ARA was not produced by them and noted an increase in market demand for their ARA products due to the recall [10][18]. - The A-share listed company, Jia Bi You Biotechnology, is under scrutiny as it is suspected to be the supplier of the problematic ARA, leading to a significant drop in its stock price [1][17]. Group 4: Financial Performance and Market Share - In 2024, despite a market share increase in the infant nutrition sector, Nestlé's overall performance in the Greater China region is projected to show negative growth, with a reported organic growth rate of -6.1% for the first three quarters of 2025 [7]. - Market data indicates that Nestlé and Wyeth hold approximately 4.9% and 4.4% market shares, respectively, in the Chinese infant formula market, trailing behind competitors like Feihe and Danone [7].

Core Viewpoint - The incident involving the recall of infant formula by Nestlé due to quality risks associated with ARA supplied by Jia Bi You has led to a significant drop in Jia Bi You's stock price, highlighting potential risks in the supply chain and consumer confidence in the company [2]. Group 1: Incident Overview - Nestlé announced a global preventive recall of certain batches of infant formula in 31 countries due to quality risks linked to ARA supplied by Jia Bi You [2]. - The recall affects four brands in the Chinese market, totaling 30 batches, while other Nestlé products remain unaffected [2]. - The substance Cereulide, potentially harmful and produced by Bacillus cereus, was detected in the ARA oil provided by the supplier [2]. Group 2: Company Impact - Jia Bi You's stock price fell over 13% following the announcement of the recall [2]. - The company's ARA business generated revenue of 390 million yuan in 2024, marking a year-on-year increase of 29.2%, indicating its significance to the company's core operations [3]. - Jia Bi You has stated that its ARA products have passed certifications in Europe and the U.S. and are supplied to various dairy companies [3]. Group 3: Industry Response - Other dairy companies are monitoring the situation closely, with some clarifying that they do not use the implicated ARA from Jia Bi You [3][4]. - The supply chain for infant formula ingredients is generally concentrated, which may affect the industry dynamics depending on the outcome of the investigation [4].

Core Viewpoint - The article discusses the recent recall of infant formula by Nestlé due to potential quality risks associated with ARA supplied by Jia Bi You Biotechnology, leading to a significant drop in Jia Bi You's stock price by over 13% [3]. Group 1: Incident Overview - Nestlé announced a global recall of certain batches of infant formula in 31 countries due to the detection of Cereulide in ARA oil, which is linked to Bacillus cereus and can cause foodborne illness [3]. - The recall affects four brands in the Chinese market, totaling 30 batches, while other Nestlé products remain unaffected [3]. Group 2: Company Impact - Jia Bi You's ARA business generated revenue of 390 million yuan in 2024, marking a 29.2% year-on-year increase, making it a core part of the company's operations [5]. - Following the incident, Jia Bi You has sent its products for testing and will release results once available [5]. Group 3: Industry Response - Other dairy companies have distanced themselves from the incident, stating they do not use the implicated ARA from Jia Bi You [5]. - The ARA market is concentrated among a few suppliers, and the situation is being closely monitored by industry analysts [5].